Evidence map›Paper›PMID 41923928›Full record

ArticleLiver cancer2026

Impact of Procedural Quality on Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicenter Study.

Nan Jiang, Wen Zhang, Zhenwei Peng, Chang Liu, Yu-Dong Xiao, Wei-Zhu Yang, Rong Ding, Li-Nan Yin, Jian-Qiang Jiang, Cai-Fang Ni and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nan JiangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Wen ZhangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai, China.
Zhenwei PengDepartment of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Chang LiuDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yu-Dong XiaoDepartment of Radiology, The Second Xiangya Hospital of Central South University, Changsha, China.
Wei-Zhu YangDepartment of Interventional Radiology, Union Hospital of Fujian Medical University, Fuzhou, China.
Rong DingDepartment of Minimally Invasive International Therapy, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, China.
Li-Nan YinDepartment of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin, China.
Jian-Qiang JiangDepartment of Interventional Therapy, Nantong Tumor Hospital, Nantong, China.
Cai-Fang NiDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhi-Ping YanDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai, China.
Ming KuangDepartment of Liver Surgery, Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Gao-Jun TengCenter of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging and Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Bin-Yan ZhongDepartment of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Transarterial chemoembolization (TACE) is the primary treatment modality for intermediate-stage hepatocellular carcinoma (HCC). However, the lack of standardization to optimal technique leads to a wide variation in outcomes. This study aimed to evaluate the impact of procedure quality of TACE on HCC management. Methods: This multicenter retrospective cohort study included HCC patients with ≤4 tumors (maximum diameter ≤7 cm) treated with TACE monotherapy as first-line treatment between January 2009 and December 2022. Patients were classified into precision TACE and non-precision TACE groups based on adherence to predefined technical criteria encompassing angiography, catheterization, embolic agents, embolization endpoints, and assessment. The procedural quality was further stratified using a scoring system (where points were deducted for technical deficiencies). The primary outcome was objective response rate (ORR) after first TACE (first ORR) based on modified Response Evaluation Criteria in Solid Tumors. Secondary outcomes included overall ORR, progression-free survival (PFS), overall survival (OS), and safety profiles. Results: The analysis included 3,059 patients (median age, 58.00 years [IQR: 49.00-66.00]; 2,592 males [84.7%]) with 2,286 patients included in precision TACE and 773 patients included in non-precision TACE group. First ORR was 59.4% (1,359/2,286) in the precision TACE group versus 47.0% (363/773) in the non-precision TACE group ( Conclusion: Precision TACE was associated with improved outcomes and safety in HCC. The proposed scoring system correlates with treatment outcomes, suggesting its utility as a quality assessment tool for TACE procedures.

Indexed as

Adverse eventsHepatocellular carcinomaOutcomesProcedure qualityTransarterial chemoembolization

Identifiers

PMID41923928
PMCPMC13038286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.